Release of Methyl CpG Binding Proteins and Histone Deacetylase 1 from the Estrogen Receptor α (ER) Promoter upon Reactivation in ER-Negative Human Breast Cancer Cells
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Estrogen receptor alpha (ER) is an epigenetically regulated gene. Inhibitors of DNA methyltransferases (DNMTs) and histone deacetylases (HDACs) synergistically activate the methylated ER gene promoter in ER-negative MDA-MB-231 human breast cancer cells. Chromatin immunoprecipitation was used to examine the chromatin status and repressor complex associated with silenced ER and changes in the key regulatory factors during reactivation by inhibitors of DNMT (5-aza-2'-deoxycytidine) and HDAC (trichostatin A). The silencing of ER due to CpG hypermethylation correlates with binding of specific methyl-binding proteins, DNMTs, and HDAC proteins. Inhibition of HDAC activity by trichostatin A results in the accumulation of hyperacetylated core histones. The activation of ER gene expression by 5-aza-2'-deoxycytidine also involves the release of the repressor complex involving various methyl-binding proteins, DNMTs, and HDAC1. HDAC and DNMT inhibitors modulate histone methylation at H3-K9 and H3-K4 to form a more open chromatin structure necessary for reactivation of silenced ER transcription. Together these results impart a better understanding of molecular mechanisms of chromatin remodeling during ER reactivation by DNMT and HDAC inhibitors. These findings will aid in the application of agents targeting epigenetic changes in the treatment of breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Okano, M., Bell, D. W., Haber, D. A., & Li, E. (1999) · Cell · doi:10.1016/s0092-8674(00)81656-6 · Cited by 6,143
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001) · Nature · doi:10.1038/35065138 · Cited by 2,903
Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868
Regulation of chromatin structure by site-specific histone H3 methyltransferases
Rea, S., Eisenhaber, F., O'Carroll, D., Strahl, B. D., Sun, Z.-W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., et al. (2000) · Nature · doi:10.1038/35020506 · Cited by 2,845
Role of Histone H3 Lysine 9 Methylation in Epigenetic Control of Heterochromatin Assembly
Nakayama, J.-I., Rice, J. C., Strahl, B. D., Allis, C. D., & Grewal, S. I. S. (2001) · Science · doi:10.1126/science.1060118 · Cited by 1,739
Zhang, Y., Ng, H.-H., Erdjument-Bromage, H., Tempst, P., Bird, A., & Reinberg, D. (1999) · Genes & Development · doi:10.1101/gad.13.15.1924 · Cited by 1,103
Methyl CpG-binding proteins and transcriptional repression
Wade, P. A. (2001) · BioEssays · doi:10.1002/bies.10008 · Cited by 351
Cited by
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Quantitation of HDAC1 mRNA Expression in Invasive Carcinoma of the Breast*
Zhang, Z., Yamashita, H., Toyama, T., Sugiura, H., Ando, Y., Mita, K., Hamaguchi, M., Hara, Y., Kobayashi, S., & Iwase, H. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-6001-1 · Cited by 305
Bhandari, R. K., Deem, S. L., Holliday, D. K., Jandegian, C. M., Kassotis, C. D., Nagel, S. C., Tillitt, D. E., vom Saal, F. S., & Rosenfeld, C. S. (2015) · General and Comparative Endocrinology · doi:10.1016/j.ygcen.2014.09.014 · Cited by 297
Tamoxifen Resistance in Breast Cancer
Chang, M.-S. (2012) · Biomolecules and Therapeutics · doi:10.4062/biomolther.2012.20.3.256 · Cited by 285
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells
Billam, M., Sobolewski, M. D., & Davidson, N. E. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0420-3 · Cited by 158
Self-citationSabnis, G. J., Goloubeva, O., Chumsri, S., Nguyen, N., Sukumar, S., & Brodie, A. M. H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2458 · Cited by 158
“Studies conducted by Davidson and colleagues suggested that the loss of ERa protein expression is the result of the hypermethylation of the CpG islands within the ERa promoter (5, 26).”
BackgroundEstrogen Regulation of MicroRNA Expression
Klinge, C. (2009) · Current Genomics · doi:10.2174/138920209788185289 · Cited by 156
ERα and ERβ expression and transcriptional activity are differentially regulated by HDAC inhibitors
Duong, V, Licznar, A., Margueron, R., Boulle, N., Busson, M., Lacroix, M., Katzenellenbogen, B. S., Cavaillès, V, & Lazennec, G. (2006) · Oncogene · doi:10.1038/sj.onc.1209102 · Cited by 75
MEYER, J. L., ZIMBARDI, D., PODGAEC, S., AMORIM, R. L., ABRÃO, M. S., & RAINHO, C. A. (2014) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2014.1637 · Cited by 47
Prevalence, clinical investigation, and management of gallbladder disease in Rett syndrome
Freilinger, M., Böhm, M., Lanator, I., Vergesslich‐Rothschild, K., Huber, W., Anderson, A., Wong, K., Baikie, G., Ravikumara, M., Downs, J., et al. (2014) · Developmental Medicine & Child Neurology · doi:10.1111/dmcn.12358 · Cited by 17
Metadata
- Authors
- Sharma, D., Blum, J., Yang, X., Beaulieu, N., Macleod, A. R., & Davidson, N. E.
- Venue
- Molecular Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2005-07
- Volume
- 19
- Issue
- 7
- Pages
- 1740-1751
- ISSN
- 0888-8809 (ISSN-L)
- 1944-9917
- OpenAlex
- W2129940569
- Cited by
- 155
- References
- 8
- FWCI
- 3.00
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.